Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, reflecting a year-on-year increase of over 60% [1] Group 1 - 2025 marks a milestone year for the company as product revenue surpasses RMB 10 billion, demonstrating the success of its "dual-driven and global innovation" strategy [2] - The company has expanded its oncology product portfolio to 13 products, with core products like Darbeshou® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [2] - The company has successfully entered the chronic disease commercialization sector, leveraging unmet needs and strong product competitiveness to drive growth [2] Group 2 - Key emerging drivers of revenue growth include Xinermy® (masitinib injection), Xinbile® (toripalimab injection), and Xinbimin® (teplizumab injection), which are experiencing accelerated market uptake [2] - Another important product, Xinmeiyue® (picanquizumab injection), received approval for market launch by the end of 2025 [2] - The company's performance in 2025 reaffirms its excellent commercialization capabilities and sustainable business development model [2] Group 3 - The company is making significant progress in its global innovation pipeline, focusing on next-generation immunotherapies (IO) and antibody-drug conjugates (ADC), as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - These advancements are expected to create additional growth opportunities and support the company's vision of becoming a leading international biopharmaceutical company [3]
信达生物(01801)2025年实现总产品收入约119亿元 同比保持约45%的强劲增长态势